Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Reviva Pharmaceuticals Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Reviva Pharmaceuticals Holdings, Inc.’s stock price such as:

• Reviva Pharmaceuticals Holdings, Inc.’s current stock price and volume
• Why Reviva Pharmaceuticals Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for RVPH from analysts
• RVPH’s stock price momentum as measured by its relative strength

About Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Before we jump into Reviva Pharmaceuticals Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company’s lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention–deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer’s disease, and Parkinson’s disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

Want to learn more about Reviva Pharmaceuticals Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Reviva Pharmaceuticals Holdings, Inc..

Reviva Pharmaceuticals Holdings, Inc.’s Stock Price as of Market Close

As of January 14, 2025, 4:00 PM, CST, Reviva Pharmaceuticals Holdings, Inc.’s stock price was $1.58.

Reviva Pharmaceuticals Holdings, Inc. is down 17.28% from its previous closing price of $1.91.

During the last market session, Reviva Pharmaceuticals Holdings, Inc.’s stock traded between $1.56 and $1.98. Currently, there are approximately 33.80 million shares outstanding for Reviva Pharmaceuticals Holdings, Inc..

Reviva Pharmaceuticals Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Reviva Pharmaceuticals Holdings, Inc. Stock Price History

Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) price is currently down 12.71% so far this month.

During the month of January, Reviva Pharmaceuticals Holdings, Inc.’s stock price has reached a high of $2.17 and a low of $1.56.

Over the last year, Reviva Pharmaceuticals Holdings, Inc. has hit prices as high as $4.83 and as low as $0.60. Year to date, Reviva Pharmaceuticals Holdings, Inc.’s stock is down 12.71%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Reviva Pharmaceuticals Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of January 13, 2025,, no analysts have changed their rating of Reviva Pharmaceuticals Holdings, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Reviva Pharmaceuticals Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Reviva Pharmaceuticals Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Reviva Pharmaceuticals Holdings, Inc. (RVPH) by visiting AAII Stock Evaluator.

Relative Price Strength of Reviva Pharmaceuticals Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of January 13, 2025, Reviva Pharmaceuticals Holdings, Inc. has a weighted four-quarter relative price strength of 4.90%, which translates to a Momentum Score of 78 and is considered to be Strong.

Want to learn more about how Reviva Pharmaceuticals Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Reviva Pharmaceuticals Holdings, Inc. Stock Price: Bottom Line

As of January 14, 2025, Reviva Pharmaceuticals Holdings, Inc.’s stock price is $1.58, which is down 17.28% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Reviva Pharmaceuticals Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.